| Autor: |
Amino I; Clinical Laboratory, Saitama Medical University International Medical Center., Maeda T; Department of Hemato-Oncology, Saitama Medical University International Medical Center., Aoki M; Clinical Laboratory, Saitama Medical University International Medical Center., Kinoshita H; Clinical Laboratory, Saitama Medical University International Medical Center., Muroya A; Clinical Laboratory, Saitama Medical University International Medical Center., Taji Y; Clinical Laboratory, Saitama Medical University International Medical Center., Kobayashi K; Clinical Laboratory, Saitama Medical University International Medical Center.; Department of Laboratory Medicine, Saitama Medical University International Medical Center., Okamura D; Department of Hemato-Oncology, Saitama Medical University International Medical Center., Murayama Y; Department of Respiratory Medicine, Saitama Medical University International Medical Center., Asou N; Department of Hemato-Oncology, Saitama Medical University International Medical Center., Ebihara Y; Clinical Laboratory, Saitama Medical University International Medical Center.; Department of Laboratory Medicine, Saitama Medical University International Medical Center. |
| Jazyk: |
japonština |
| Zdroj: |
[Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2020; Vol. 61 (8), pp. 874-878. |
| DOI: |
10.11406/rinketsu.61.874 |
| Abstrakt: |
A 74-year-old man was admitted to hospital due to suspected acute leukemia. He had a history of thymic carcinoma, which had been treated with carboplatin in combination with either paclitaxel or amrubicin. However, the tumor remained unresponsive to these treatments. Administration of tegafur/gimeracil/oteracil (TS-1) was initiated, which resulted in tumor size reduction and a partial response. However, leukopenia persisted after the last TS-1 treatment, and four years after the initial treatment, increased blast cell counts were found in a blood film . Bone marrow analysis showed blasts with Auer rods, faggot cells, and dysplastic promyelocytes. Flow cytometry was positive for CD13, CD33, CD34, CD117, and myeloperoxidase, but negative for HLA-DR. PML-RARA fluorescence in situ hybridization was positive. Cytogenetic analysis revealed 47,XY,t (15;17) (q22;q21),+21. Thus, therapy-related acute promyelocytic leukemia (tAPL) was diagnosed. The patient achieved and maintained complete remission for more than 20 months by a de novo APL-treatment regimen including all-trans retinoic acid, arsenic trioxide and tamibarotene. Moreover, the thymic carcinoma has remained stable. Although secondary malignancies of thymic carcinoma have been previously reported, therapy-related leukemia, especially tAPL, is very rare. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
